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Abstract A rapid, precise, accurate, and selective high-
performance liquid chromatographic method with ﬂuores-
cence detection has been validated and used for analysis of
amisulpride in human plasma after a simple solid-phase
extraction procedure. Compounds were separated on a CN
column with 0.03 M potassium dihydrogen phosphate (pH
6.5)–acetonitrile 65:35 (v/v) as mobile phase. Fluorescence
detection was performed at excitation and emission wave-
lengths of 274 and 370 nm, respectively. Calibration plots
werelinearovertheconcentrationrange10–1,000 ng mL
-1
in human plasma, and the lower limit of quantiﬁcation was
10 ng mL
-1. Accuracy was between 0.4 and 6.4% and
precision was between 3.1 and 7.5%. Amisulpride was
sufﬁciently stable through three freeze–thaw cycles, during
storage for 6 h at room temperature, and for 2 months at
-22 C. The method is suitable for the analysis of clinical
samples from pharmacokinetic studies.
Keywords Column liquid chromatography 
Amisulpride  Validation  Solid-phase extraction 
Pharmacokinetic study
Introduction
Amisulpride ((R,S)-4-amino-N-[(1-ethylpyrrolidin-2-yl)me-
thyl]-5-ethylsulphonyl-2-methoxybenzamide) is a 2-metho-
xybenzamide derivative chemically related to sulpiride. It
is an antagonist of dopamine D2 and D3 receptors [1]. It is
effective as an antidysthymic, antischizophrenic, or anti-
psychotic drug, depending on the dose: 50–100 mg for
treatment of dysthymic disorders [2, 3], over 200 mg for
treatment of negative symptoms in schizophrenic patients,
and over 600 mg for psychotic disorders [4].
Amisulpride is rapidly absorbed, with an absolute bio-
availability of approximately 50% and a biphasic absorp-
tion proﬁle [5, 6]. Two distinct plasma concentration peaks
are usually observed approximately 1 and 3–4 h (Tmax)
after administration. The protein binding of this drug is
approximately 17% and the average amisulpride elimina-
tion half-life from plasma, after oral administration, is
approximately 11–12 h [5, 6]. Low metabolism (approx.
5% of the administered dose) is a characteristic of ami-
sulpride, and unmodiﬁed drug is primarily excreted in the
urine (50% of an intravenous dose is excreted via the urine,
of which 90% is eliminated in the ﬁrst 24 h) [4, 5].
Several methods have been used for analysis of ami-
sulpride in human plasma, including gas chromatography
[7], radioreceptor assay [8], and high-performance liquid
chromatography (LC) with UV [9–11], mass spectrometric
[12, 13], or ﬂuorescence [14, 15] detection.
Gschwend et al. [13] reported a sensitive LC method
with mass spectrometric detection after liquid–liquid
extraction (diisopropyl ether–dichloromethane 1:1 (v/v)); a
low limit of quantiﬁcation (LLOQ) of 0.5 ng mL
-1 ami-
sulpride was achieved. Kirchherr et al. [12] used another
LC–MS method for analysis of antidepressants and
achieved an LLOQ of 28 ng mL
-1 for amisulpride.
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lation of amisulpride from plasma. Chromatographic sep-
aration on a Nucleosil 100-Protect 1 column was followed
by UV detection. Response was a linear function of con-
centration over the range 10–1,000 ng mL
-1.
A fully automated chromatographic method including
on-line blood serum or plasma clean-up, isocratic LC, and
spectrophotometric detection was reported by Sachse et al.
[10]. Plasma or serum was cleaned on a silica CN
(10 9 4.0 mm i.d., 20-lm particle) column and further
separation was performed on a LiChrospher CN column.
The limit of detection was 10 ng mL
-1 and the linear range
10–600 ng mL
-1.
Malavasi et al. [14] used both liquid–liquid extraction
and solid-phase extraction for isolation of amisulpride from
human plasma. LC separation was performed on a Hypersil
C18 BDS column. Fluorescence detection with excitation
and emission wavelengths of 280 and 370 nm, respec-
tively, resulted in a limit of quantiﬁcation of 0.5 ng mL
-1
and a calibration range of 0.5–640 ng mL
-1.
The objective of this work was to develop and validate
a rapid and sensitive LC method with simple sample
preparation for analysis of amisulpride in human plasma,
and to use it in a randomized cross-over bioequivalence
study after oral administration of two different amisulpride
preparations (200 mg) to 18 healthy volunteers. Fluores-
cence detection was chosen as more sensitive and speciﬁc
than UV detection. Most existing methods for analysis of
amisulpride in human plasma have an upper limit of
quantiﬁcation in the range 600–640 ng mL
-1. This is
suitable for study of pharmacokinetics after oral admin-
istration of 50 mg amisulpride. After an oral dose of
200 mg the expected Cmax is [500 ng mL
-1 with a
standard deviation of approximately 200 ng mL
-1, and
thus the upper limit of quantiﬁcation should be not less
than 850 ng mL
-1. Our method includes a simple single-
stage SPE procedure (loading–washing–collection). The
method was validated in accordance with FDA guidelines
[16] to assess its selectivity, sensitivity, accuracy, and
precision.
Experimental
Chemicals, Reagents, and Solutions
The amisulpride standard was a European Pharmacopoeia
standard (purity 99.9%; Council of Europe, European
Directorate for the Quality of Medicines and Health
Care, Strasbourg, France). Metoclopramide hydrochloride
(4-amino-5-chloro-N-[(2-diethylamino)ethyl]-2-methoxy-
benzamide hydrochloride; purity 99.73%), used as internal
standard (IS), was purchased from Ipca Laboratories
(Mumbai, India). The chemical structures of both sub-
stances are shown in Fig. 1.
Methanol and acetonitrile were HPLC-grade (Sigma–
Aldrich, St Louis, MO, USA). Triethylamine, orthophos-
phoric acid (85%), and potassium dihydrogen phosphate
were analytical grade (Fluka, Buchs, Switzerland). Double-
distilled water puriﬁed with a Milli-Q5 system (Millipore,
Bedford, MA, USA) was used in all experiments.
Human plasma was obtained from the Kharkov Center
of Blood Service (Kharkov, Ukraine).
Oasis HLB solid-phase extraction cartridges (1 cc,
30 mg; Waters, Milford, MA, USA) were used for sample
preparation.
Amisulpride stock standard solution (1 mg mL
-1) was
prepared in methanol. Working solutions (1.0, 2.5, 3.0, 5.0,
10, 25, 30, 50, 75, 90, and 100 lgm L
-1) were prepared by
dilution of the stock solution with pure water. These ami-
sulpride working solutions were used for preparation of
validation plasma samples (standard calibration samples
and quality-control samples) and amisulpride working
standard solutions.
Amisulpride working standard solutions were prepared
at concentrations of 20, 50, 100, 200, 500, 1,000, 1,500,
and 2,000 ng mL
-1, by dilution of 200 lL of the appro-
priate amisulpride working solution to 10 mL with water–
acetonitrile 75:25 (v/v). Amisulpride working standard
solutions were used for assessment of the linearity of
detector response.
Internal standard (metoclopramide) solution (1 mg mL
-1)
was prepared in pure water and diluted to 100 lgm L
-1
with pure water.
To prepare calibration standards, 2 mL human plasma
was mixed with 20 lL of the appropriate amisulpride
working solution to furnish concentrations of 10, 25, 50,
100, 250, 500, 750, and 1,000 ng mL
-1. The IS solution
(100 lgm L
-1,1 5 lL) was added to 1.5 mL of the
Fig. 1 The chemical structures of amisulpride and metoclopramide
(IS)
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123corresponding calibration standard and the procedure for
sample preparation, described below, was carried out.
To prepare quality-control samples 250 lL of the
appropriate amisulpride working solution was diluted with
25 mL human plasma to furnish concentrations of 30, 300,
and 900 ng mL
-1.
To prepare amisulpride samples with concentrations
above the calibration range (1,800 ng mL
-1), 500 lL
amisulpride working solution (concentration 90 lgm L
-1)
was diluted with 25 mL human plasma. This solution was
used to test the integrity of the dilution procedure.
IS solution (100 lgm L
-1,1 5lL) was added to 1.5 mL
of the corresponding validation sample and the procedure
for sample preparation, described below, was carried out.
Sample Preparation
Frozen plasma samples were thawed at ambient tempera-
ture (20 ± 2 C) and vortex-mixed for 30 s. Plasma
(1.5 mL) was placed in a plastic tube, 15 lL IS solution
(100 lgm L
-1) was added, and vortex mixing was per-
formed for 30 s. Samples were centrifuged at 11,000g for
15 min. After centrifugation, 1.0 mL of the supernatant
was loaded on to a previously activated SPE cartridge. The
cartridge was washed with 1 mL pure water then the
amisulpride and metoclopramide were eluted with 1.0 mL
methanol. The eluent was collected in a polypropylene tube
and evaporated to dryness under vacuum at 58 C. The
residue was reconstituted with 500 lL water–acetonitrile
mixture 75:25 (v/v) and the solution was vortex-mixed and
analyzed.
Instrumentation and Chromatographic Conditions
HPLC was performed with a Perkin Elmer (Shelton, USA)
series 200 system consisting of vacuum degasser, gradient
pump, thermostatic autosampler, column oven, ﬂuores-
cence detector, diode-array detector, and network chro-
matographic interface (NCI 900). TotalChrom ver. 6.0
software (Perkin Elmer) was used for acquisition and
processing of chromatographic data.
Chromatographic separation was performed at 35 Co n
a 250 9 4.6 mm i.d., particle size 5 lm, Zorbax SB-CN
analytical column (Agilent Technologies, USA) with a
12.5 9 4.6 mm i.d., particle size 5 lm, Zorbax SB-CN
guard column (Agilent). The mobile phase was 0.03 M
phosphate buffer (pH 6.5)–acetonitrile 65:35 (v/v). The
0.03 M phosphate buffer solution (pH 6.5) was prepared by
dissolving 4.1 g potassium dihydrogen phosphate in
950 mL pure water, adjusting to pH 6.5 ± 0.1 with tri-
ethylamine, and diluting to 1,000 mL with pure water. The
mobile phase ﬂow-rate was 1 mL min
-1 and the injection
volume was 40 lL. Fluorescence detection (excitation and
emission wavelengths 274 and 370 nm, respectively) was
used for detection of amisulpride and the IS.
Optimization of SPE
Solid-phase extraction (SPE) was chosen for sample prep-
aration. This method enables simultaneous and rapid pro-
cessing of many samples, cleaning extracts from biological
material and concentration of determined compounds.
Oasis HLB cartridges were chosen for extraction of
amisulpride and the internal standard from plasma samples.
These cartridges contain adsorbent with both hydrophobic
and hydrophilic properties. Preliminary sample extraction
conditions were selected by using aqueous solutions the
compounds investigated. The amisulpride and IS content of
washings from the cartridge were determined after each
stage of sample preparation (sorption, washing, and col-
lection). Sample-preparation conditions were the same as
those proposed by the cartridge manufacturer: conditioning
(pre-washing) with 1 mL methanol then 1 mL water,
washing with water and 30% (v/v) methanol–water, then
collection by use of 1 mL methanol. Amisulpride and the IS
were not found in the washing liquids after the adsorption
and washing stages. The methanolic sample solution
obtained in the collection stage was dried under vacuum and
the residue was re-dissolved in 1.0 mL water–acetonitrile
75:25 (v/v). The amisulpride and IS content were approxi-
mately 90 and 80%, respectively, of the theoretical values
(determined by analysis of solutions containing the com-
pounds without the sample-preparation stage).
After development, sample extraction was performed on
plasma containing known concentrations of analyte and IS.
Endogenous plasma components did not interfere with the
compounds of interest after their isolation by use of SPE.
Pure acetonitrile, a mixture of equal volumes of acetonitrile
and methanol, and double the volume of methanol were
used as liquids for collection of amisulpride and IS but,
because these solvents did not lead to more efﬁcient
extraction, 1 mL methanol was chosen for collection.
Optimization of LC
High-performance liquid chromatography with different
methods of detection have been used for pharmacokinetic
studies of amisulpride. We compared the sensitivity for
amisulpride using the same chromatographic conditions
but with application of diode-array and ﬂuorescence
detection. The DAD was set at the wavelength of maxi-
mum absorption, 274 nm, and ﬂuorescence detection was
performed with excitation and emission wavelengths of
274 and 370 nm, respectively. It was established that under
similar chromatographic conditions ﬂuorescence detection
was six times more sensitive that UV detection.
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123Because the CN stationary phase used is more polar than
C8 and C18 it enables faster separation with low mobile
phase organic modiﬁer content.
In bioanalysis, LC retention of the analytes should be
sufﬁcient to avoid interferences with the ﬁrst peak in the
chromatogram. For this reason, the effect of mobile phase
pH on analyte retention was studied. Mobile phase pH
tested was 6.0, 6.5, and 7.0. It was found that retention of
amisulpride in this pH range did not vary signiﬁcantly. Use
of an acidic (pH 3.0) mobile phase, however, substantially
reduced retention and resolution of amisulpride and the IS.
Reduction of the acetonitrile content led to increased
retention time and resolution of amisulpride and IS, but
separation of the analyte from endogenous components of
the plasma was not achieved. The pH eventually selected
was 6.5.
To achieve good retention of amisulpride and good
resolution between amisulpride and IS the effect of the
acetonitrile content of the mobile phase was studied. The
retention time of amisulpride and amisulpride–IS resolu-
tion were determined using acetonitrile concentrations
ranging from 25 to 50% (v/v). The retention times and
resolution of the analytes decreased as the concentration of
organic modiﬁer was increased (Table 1). The ﬁnal ace-
tonitrile concentration selected was 35% (v/v).
Results and Discussion
Validation
The method was validated in accordance with USP 32 [17],
International Conference of Harmonization (ICH) Guide-
lines [16, 18, 19], and other literature [20].
Selectivity
Selectivity is the ability of an analytical method to differ-
entiate and quantify the analyte in the presence of other
components of the sample; selectivity should be ensured at
the lower limit of quantiﬁcation (LLOQ). Six blank plasma
samples from different sources were used for evaluation of
method selectivity. Blank samples were tested for inter-
ference with the analyte and the IS. The selectivity crite-
rion was that the maximum interference observed in blank
plasma samples should not exceed one-ﬁfth of the analyte
response at the LLOQ [16].
Chromatograms obtained from blank human plasma,
plasma spiked with amisulpride (10 ng mL
-1; LLOQ) and
metoclopramide (IS, 1,000 ng mL
-1) and from plasma
spiked with amisulpride (1,000 ng mL
-1; upper limit of
quantiﬁcation, ULOQ) and the IS are presented in Fig. 2,
from which it apparent no interference was detected. The
spectral purity of the peaks of amisulpride and the IS was,
furthermore, monitored by use of the DAD and found to be
more than 99% for both at the ULOQ level.
Linearity
The linearity of detector response was estimated by anal-
ysis of working standard solutions of amisulpride in the
concentration range 20–2,000 ng mL
-1. The dependence
of detector response (peak area) on amisulpride concen-
tration was described by the equation Y = 2060.3C ?
998.26, r = 0.9996 (where Y is peak area, C is amisulpride
concentration in ng mL
-1, and r is the correlation
coefﬁcient).
The linearity of the method was evaluated by con-
structing a calibration plot in the range 10–1,000 ng mL
-1
amisulpride in plasma by plotting the amisulpride-
to-internal standard peak-area ratio against amisulpride
concentration. Least-squares linear regression analysis with
the weighting coefﬁcient 1/C
2 was used to determine
the relationship between amisulpride concentration and
detector response.
Each day the slope, intercept, and correlation coefﬁcient
were determined; results of these investigations are pre-
sented in Table 2. The resulting calibration equation was
Y = (18.3 ± 0.7) 9 10
-4C ? (6 ± 15) 9 10
-4,
r = 0.9979; the relationship between peak-area ratio and
amisulpride concentration was linear within the concen-
tration range studied.
The limit of detection (LOD) of amisulpride in plasma
samples was 2 ng mL
-1 (the serial dilution method was
used; signal-to-noise ratio = 3). The lowest limit of
quantiﬁcation (LLOQ) was deﬁned as the lowest concen-
tration in the linear region of the calibration plot for which
the coefﬁcient of variation (CV) was reproducibly below
Table 1 Dependence of amisulpride retention on the amount of
acetonitrile in the mobile phase
Amount of
acetonitrile (%)
Component Retention
time
k Resolution
25 AMS 13.63 3.96 5.24
IS 16.92 5.15
30 AMS 10.28 2.74 5.08
IS 12.77 3.64
35 AMS 8.97 2.26 4.78
IS 11.10 3.04
40 AMS 7.98 1.90 4.35
IS 9.74 2.54
45 AMS 7.35 1.67 3.94
IS 8.84 2.16
50 AMS 7.05 1.57 3.69
IS 8.41 2.06
AMS amisulpride, IS internal standard (metoclopramide)
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LLOQ from ﬁve determinations was 10 ng mL
-1.
Accuracy and Precision
Accuracy and precision were determined by replicate anal-
ysis of samples with known amisulpride content. The mean
value should be within 15% of the actual value [16, 20, 21].
The difference between mean amounts of amisulpride added
and recovered (RE, %) serves as a measure of accuracy. The
coefﬁcient of variation (CV, %), as a measure of precision at
each concentration, should not exceed 15%.
Intra-day and inter-day accuracy and precision were
evaluated by analysis of quality-control samples contain-
ing amisulpride at three different concentrations—a low
concentration (LQC), 30 ng mL
-1, a concentration near
the centre of the calibration plot (MQC), 300 ng mL
-1,
and a concentration near the upper limit of the calibration
plot (HQC), 900 ng mL
-1. Intra-day accuracy and preci-
sion were evaluated by analysis of these QC samples
prepared and analyzed on 1 day (eight samples of each
concentration; three replicate injections). Inter-day accu-
racy and precision were evaluated by analysis of these
QC samples prepared and analyzed on ﬁve different days
Fig. 2 Chromatograms
obtained from a Blank human
plasma; b Plasma spiked at the
LLOQ (10 ng mL
-1
amisulpride and 1,000 ng mL
-1
metoclopramide (IS)); c Plasma
spiked at the ULOQ
(1,000 ng mL
-1 amisulpride
and 1,000 ng mL
-1
metoclopramide)
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injections).
The dilution procedure for plasma samples containing
amisulpride concentrations outside the calibration range
was validated by analysis of eight diluted samples with an
amisulpride concentration of 1,800 ng mL
-1 (2 9 HQC),
and evaluation of accuracy and precision from the results
obtained.
The intra-day and inter-day precision and accuracy of
the method are presented in Table 3. Intra-day precision
ranged between 3.13 and 5.35% and inter-day precision
was between 4.54 and 7.50%. Intra-day accuracy was
between -3.00 and 6.41% and inter-day accuracy was
between 0.40 and 4.11%. Precision and accuracy of anal-
ysis of diluted samples were also satisfactory.
All values for accuracy and precision were within the
recommended limits.
Recovery
Recovery of amisulpride and the IS from plasma was
determined at concentrations of 30, 300, and 900 ng mL
-1
for amisulpride and 1,000 ng mL
-1 for metoclopramide by
comparing peak areas obtained from plasma with those
obtained from the same amounts of unextracted solutions
[16]. Recovery was 94% for amisulpride and 95% for
metoclopramide.
Stability
The stability of amisulpride in human plasma over three
freeze–thaw cycles and during short-term, long-term, and
post-preparative storage was tested by analysis of LQC
(30 ng mL
-1) and HQC (900 ng mL
-1) samples [16].
The freeze–thaw stability of the amisulpride was deter-
mined over three freeze–thaw cycles within 3 days. Spiked
plasma samples were frozen at -22 C for 24 h and thawed
at room temperature in each freeze–thaw cycle. To study
short-term stability, the frozen (-22 C) and then thawed
plasmasamples werekeptatroomtemperaturefor6 hbefore
sample preparation. The postpreparative stability of prepared
plasma samples was studied after keeping the samples in the
autosampler at 16 C for 48 h. The results obtained from
these test samples were compared with those from freshly
thawed and processed samples (reference samples).
Long-term stability was determined after keeping spiked
plasma samples frozen at -22 C for 2 months. For this
stability test the samples (test samples) were analyzed and
the results were compared with those obtained from freshly
prepared and processed samples (reference samples) [22].
The stability of amisulpride and metoclopramide (IS) in
stock solutions was studied after storage at 2 C for 1 month.
The results obtained from assessment of stability are
given in Table 4. Three freeze–thaw cycles of the quality-
control samples did not seem to affect quantiﬁcation of the
amisulpride. Quality-control samples stored in a freezer at
-22 C were stable for at least 2 months. Thawing of the
frozen samples and keeping them at room temperature for
6 h had no effect on quantiﬁcation. Prepared samples
stored in autosampler at 16 C were stable for at least 48 h.
The stability of amisulpride and metoclopramide in stock
solutions was conﬁrmed after storage for 29 days at 2 C.
Bioequivalence Study
The applicability of the method was demonstrated in
a randomized crossover bioequivalence study of two
Table 2 Calibration plot data for amisulpride in human plasma
Day Slope Intercept r
1 0.001882 -0.002320 0.9998
2 0.001865 -0.001105 0.9970
3 0.001890 -0.000968 0.9957
4 0.001764 -0.000368 0.9995
5 0.001735 0.001759 0.9973
Mean 0.001827 0.000600 0.9979
SD 7.2 9 10
-5 0.001497 0.0018
Table 3 Intra-day (n = 8) and
inter-day (n = 3 9 5) precision
and accuracy of LC analysis of
amisulpride in QC samples
QC sample
(ng mL
-1)
Dilution
factor
Measured concentration
(ng mL
-1; mean ± SD)
Accuracy
(RE, %)
Precision
(CV, %)
Intra-day
30 1 29.2 ± 1.0 -2.56 3.51
300 1 319 ± 17 6.41 5.34
900 1 893 ± 28 -0.77 3.13
1,800 2 1,746 ± 93 -3.00 5.35
Inter-day
30 1 30 ± 2 0.40 7.50
300 1 309 ± 16 3.24 5.17
900 1 937 ± 41 4.11 4.54
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123amisulpridepreparations—Solian200 mg(SanoﬁWinthrop
Industrie, Gentille, France), used as the reference prepara-
tion, and Soleron 200 (Pharma Start, Kyiv, Ukraine) the
investigated preparation.
Eighteen healthy volunteers (ten male and eight female),
age 26–30 years, weight 53–85 kg, participated in the
study. The subjects were underwent a clinical examination,
electrocardiogram, and laboratory tests. The investigation
was approved by the Ethics Committee and written
informed consent was obtained from all the subjects. No
volunteer took any drug for at least 14 days before the
study or during it.
The volunteers were randomly divided into two groups
of nine. The study was divided into two periods with a
6-day washout period. In the ﬁrst period, group 1 received
the reference preparation and group 2 received the test
preparation. A crossover design was used in the study: in
the second period, group 1 received the test preparation and
group 2 the reference preparation.
A single oral dose of amisulpride (200 mg) was
administrated under fasting conditions and serial blood
samples were collected at suitable intervals up to 36 h.
Pharmacokinetic data including the area under the con-
centration–time curve during the sampling period
(AUC0–36), the area under the concentration–time curve
from zero to inﬁnity (AUC0–?), and elimination half life
(T1/2) were calculated by use of WinNonLin v. 5.2 (Phar-
sight, USA) pharmacokinetics software. The maximum
plasma concentration (Cmax) and the time to reach the peak
plasma concentration (Tmax) were obtained directly from
the individual drug plasma concentration–time plots.
Table 4 Results from testing of the stability of amisulpride in human plasma (n = 6)
Stability test Test samples Reference samples Test/reference
(%)
Measured concentration
(ng mL
-1; mean ± SD)
Accuracy
(RE, %)
Precision
(CV, %)
Measured concentration
(ng mL
-1; mean ± SD)
Accuracy
(RE, %)
Precision
(CV, %)
LQC level
Short-term 27.8 ± 0.4 -7.26 1.59 28.5 ± 1.1 -5.00 3.96 -2.38
Freeze–thaw 27.7 ± 1.1 -7.65 3.84 28.5 ± 1.1 -5.00 3.96 -2.79
Post preparative 29.10 ± 0.42 -3.01 1.43 28.5 ± 1.1 -5.00 3.96 2.09
Long-term 30.4 ± 0.8 1.35 2.66 31.3 ± 0.6 4.25 2.01 -2.78
HQC level
Short-term 829 ± 33 -7.92 3.95 836 ± 10 -7.14 1.18 -0.85
Freeze–thaw 845 ± 11 -6.15 1.29 837 ± 10 -7.14 1.18 1.06
Post preparative 852 ± 12 -5.38 1.31 836 ± 10 -7.14 1.18 1.89
Long-term 947 ± 22 5.19 2.31 972 ± 7 8.00 0.70 -2.60
Fig. 3 Mean plasma concentration–time proﬁles of amisulpride for
the test (a) and reference (b) preparations, obtained after adminis-
tration of a single 200-mg oral dose to 18 human volunteers
Table 5 Mean (±SD) pharmacokinetic data for two amisulpride
preparations after administration of a single 200-mg oral dose to 18
human volunteers
Test preparation Reference preparation
Tmax (h) 4.8 ± 0.8 4.5 ± 0.8
Cmax (ng mL
-1) 501 ± 216 515 ± 208
AUC0–36 (ng h mL
-1) 3,193 ± 976 3,311 ± 1,144
AUC0–? (ng h mL
-1) 3,362 ± 1,003 3,483 ± 1,137
T1/2 (h) 7.4 ± 2.2 6.8 ± 3.5
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and all statistical calculations were deﬁned at the level
P B 0.05. Typical pharmacokinetic proﬁles (plasma con-
centration–time) for the two amisulpride preparations are
presented in Fig. 3 and the main pharmacokinetic data are
summarized in Table 5.
Conclusion
A simple, accurate, rapid, and selective reversed-phase LC
method with ﬂuorescence detection for analysis of ami-
sulpride in human plasma after its isolation by solid-phase
extraction has been developed and validated. A one-step
solid-phase extraction procedure is proposed for prepara-
tion of plasma samples for analysis of amisulpride during
pharmacokinetic investigations.
The sensitivity of the method (LLOD) was almost the
same as that described in the literature for analogous phar-
macokinetic studies, but in this method the amisulpride
ULOQwas increased substantially—up to 1,000 ng mL
-1—
because the orally administered dose was increased to
200 mg compared with 50 mg investigated previously, and
because of the need to perform pharmacokinetic investiga-
tions with this pharmaceutical preparation (Soleron 200).
The method was successfully applied to a bioequiva-
lence study of two amisulpride preparations after oral
administration of a 200-mg dose to eighteen healthy vol-
unteers. It was demonstrated that both amisulpride prepa-
rations had similar pharmacokinetic properties.
Acknowledgments This work was supported by Pharma Start Ltd,
(Kyiv, Ukraine), sponsor of the bioequivalence study of two ami-
sulpride preparations (Solian 200 mg, Sanoﬁ Winthrop Industrie S.A.,
Gentille, France and Soleron 200, Pharma Start, Kyiv, Ukraine).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Coukell AJ, Spencer CM, Benﬁeld P (1996) CNS Drugs
6:237–243
2. Costa JA, Silva E (1990) Ann Psychiatr 5:242–256
3. Agnoli A, Ravizza L, Torta R (1989) In: Proc 37th Italian
Psychiatry Society Congress, Rome, 6–11 February 1989, CIC
International, Rome
4. Josserand F, Weber F (1988) Ann Psychiatr 3:306–312
5. Noble S, Benﬁeld P (1999) CNS Drugs 12:471–477
6. Hamon-Vilcot B, Chaufour S, Deschamps C, Canal M, Zieleniuk
I, Ahtoy P, Chretien P, Rosenzweig P, Nasr A, Piette F (1998)
Eur J Clin Pharmacol 54:405–415
7. Kamizono A, Inotsume N, Miyamote K, Ueda K, Miyakawa T,
Arimoto H, Nakano M (1991) J Chromatogr B 567:113–119
8. Mokrim R, Brunet C, Cazin M, Gressier B, Luyckx M, Dine T,
Robert H, Cazin JC (1993) Methods Find Exp Clin Pharmacol
15:41–50
9. Frahnert C, Rao ML, Grasma ¨der K (2003) J Chromatogr B
794:35–40. doi:10.1016/S1570-0232(03)00393-3)
10. Sachse J, Ha ¨rtter S, Weigmann H, Hiemke C (2003) J Chroma-
togr B 784:405–411. doi:10.1016/S1570-0232(02)00808-5
11. Pehourcq F, Ouariki S, Begaud B (2003) J Chromatogr B
789:101–117. doi:10.1016/S1570-0232(03)00045-X
12. Kirchherr H, Ku ¨hn-Velten WN (2006) J Chromatogr B
843:100–105. doi:10.1016/j.jchromb.2006.05.031
13. Gschwend MH, Arnold P, Ring J, Martin W (2006) J Chromatogr
B 831:132–140. doi:10.1016/j.jchromb.2005.11.042
14. Malavasi B, Locatell M, Ripamonti M, Ascalone V (1996)
J Chromatogr B 676:107–112
15. Ascalone V, Ripamonti M, Malavasi B (1996) J Chromatogr B
676:95–101
16. Guidance for industry, bioanalytical method validation. US
Department of Heaths and Human Services, Food and Drug
Administration, Center for Drug Evaluation and Research
(CDER), Rockville, MD, 2001. http://www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm064
964.htm
17. United States Pharmacopoeia 32/National Formulary 27 (2009)
United State Pharmacopoeial Convention. Rockville, MD,
pp 733–740
18. International Conference of Harmonization, Q2A: Text on vali-
dation of analytical procedures. (1995) US FDA Federal Register,
V. 60, March, pp 11260–11273
19. International Conference of Harmonization, Q2B: Validation of
analytical procedures: methodology. (1997) US FDA Federal
Register, V. 62, May, pp 27463–27495
20. Bansal S, DeStefano A (2007) AAPS J 9:109–115. doi:10.1208/
aapsj0901011
21. Viswanathan C, Bansal S, Booth B, DeStefano A, Rose M,
Sailstad J, Shah V, Skelly J, Swann P, Weiner R (2007) AAPS J
9:30–38. www.aapsj.org (doi:10.1208/aapsj0901004)
22. Nowatzke W, Woolf E (2007) AAPS J 9:117–122. doi:10.1208/
aapsj0902013
74 I. V. Kudris et al.
123